Dan Jones

13.1k citations
262 papers · 9.2k · h-index 53

Impact in

  • Hematology top 0.1%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 0.1%
    • Chronic Lymphocytic Leukemia Research

Papers in

  • Hematology 108
    • Chronic Myeloid Leukemia Treatments 90
    • Acute Myeloid Leukemia Research 33
  • Genetics 101
    • Chronic Lymphocytic Leukemia Research 85
Co-authors
Hagop M. Kantarjian (92 shared papers)Jörge E. Cortes (78 shared papers)Susan O’Brien (49 shared papers)Guillermo Garcia‐Manero (32 shared papers)L. Jeffrey Medeiros (41 shared papers)Srđan Verstovšek (33 shared papers)Francis J. Giles (26 shared papers)Elias Jabbour (24 shared papers)
Journals
Blood (79 papers)American Journal of Clinical Pathology (27 papers)Cancer (14 papers)Journal of Clinical Oncology (11 papers)Modern Pathology (10 papers)
Partner nations
United StatesGermanyTaiwan

In The Last Decade

Dan Jones

254 papers receiving 8.8k citations

Peers

Dan Jones
Comparison fields: 5 of 143
  • Hematology 4.7k
  • Genetics 3.6k
  • Rheumatology 1.9k
  • Pathology and Forensic Medicine 2.2k
  • Dermatology 957
Replace Naveen Pemmaraju with:
Naveen Pemmaraju United States
Rajyalakshmi Luthra United States
Steven Coutré United States
James W. Vardiman United States
Steven L. Allen United States
Michinori Ogura Japan
Gert J. Ossenkoppele Netherlands
Tapan M. Kadia United States
Naval Daver United States
Oliver G. Ottmann Germany
Dan Jones relative to Naveen Pemmaraju United States Naveen Pemmaraju's profile →
Citations per field
00.5×2×2.9×
Naveen Pemmaraju · 1×
Citations per year

Countries citing papers authored by Dan Jones

Since Specialization
Citations

This map shows the geographic impact of Dan Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Jones more than expected).

Fields of papers citing papers by Dan Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Jones. The network helps show where Dan Jones may publish in the future.

Co-authors

The 25 scholars most cited alongside Dan Jones, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dan Jones Line = papers co-authored together Dan Jones links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 262 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
Leukemia ·Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Moshe Talpaz, N. Bekele, Susan O’Brien, Xian Zhou, Rajyalakshmi Luthra, Guillermo Garcia‐Manero, Francis J. Giles, Mary Beth Rios, Srđan Verstovšek, Jörge E. Cortes
2006324
2
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Blood ·Francis J. Giles, Jörge E. Cortes, Dan Jones, Donald A. Bergstrom, Hagop M. Kantarjian, Steven J. Freedman
2006286
3
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Journal of Clinical Oncology ·Farhad Ravandi, E Estey, Dan Jones, Stefan Faderl, Susan O’Brien, Jackie Fiorentino, Sherry Pierce, Deborah Blamble, Zeev Estrov, William G. Wierda, Alessandra Ferrajoli, Srđan Verstovšek, Guillermo Garcia‐Manero, Jörge E. Cortes, Hagop M. Kantarjian
2008284
4
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
Blood ·Elihu H. Estey, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Stefan Faderl, Srđan Verstovšek, Dan Jones, Hagop M. Kantarjian
2005280
5
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia
Blood ·Farhad Ravandi, Susan O’Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey L. Jorgensen, Partow Kebriaei, Richard E. Champlin, Gautam Borthakur, Jan A. Burger, Alessandra Ferrajoli, Guillermo Garcia‐Manero, William G. Wierda, Jörge E. Cortes, Hagop M. Kantarjian
2010252
6
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Blood ·Jörge E. Cortes, Elias Jabbour, Hagop Kantarjian, C. Cameron Yin, Jianqin Shan, Susan O’Brien, Guillermo Garcia‐Manero, Francis J. Giles, Megan Breeden, Nubia Reeves, William G. Wierda, Dan Jones
2007242
7
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Clinical Cancer Research ·Jörge E. Cortes, Moshe Talpaz, Susan O’Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis J. Giles, Stefan Faderl, Srđan Verstovšek, Guillermo Garcia‐Manero, Mary Beth Rios, Hagop M. Kantarjian
2005209
8
Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
Journal of Clinical Oncology ·Jörge E. Cortes, Dan Jones, Susan O’Brien, Elias Jabbour, Farhad Ravandi, Charles Koller, Gautam Borthakur, Brenda Walker, Weiqiang Zhao, Jianqin Shan, Hagop M. Kantarjian
2009201
9
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology ·Jörge E. Cortes, Dan Jones, Susan O’Brien, Elias Jabbour, Marina Konopleva, Alessandra Ferrajoli, Tapan M. Kadia, Gautam Borthakur, Denise Stigliano, Jianqin Shan, Hagop M. Kantarjian
2009195
10
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Blood ·Ayalew Tefferi, Jörge E. Cortes, Srđan Verstovšek, Ruben A. Mesa, Deborah A. Thomas, Terra L. Lasho, William J. Hogan, Mark R. Litzow, Jacob B. Allred, Dan Jones, Catriona Byrne, Jerome B. Zeldis, Rhett P. Ketterling, Rebecca F. McClure, Francis J. Giles, Hagop M. Kantarjian
2006187
11
Primary-Effusion Lymphoma and Kaposi's Sarcoma in a Cardiac-Transplant Recipient
New England Journal of Medicine ·Dan Jones, Mary E. Ballestas, Kenneth M. Kaye, James M. Gulizia, Gayle L. Winters, Jonathan A. Fletcher, David T. Scadden, Jon C. Aster
1998146
12
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-α
Blood ·Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Rajyalakshmi Luthra, Francis J. Giles, Srđan Verstovšek, Stefan Faderl, Deborah A. Thomas, Guillermo Garcia‐Manero, Mary Beth Rios, Jianqin Shan, Dan Jones, Moshe Talpaz
2004133
13
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
Cancer ·Anas Younes, Jorge Romaguera, Frederick Hagemeister, Peter McLaughlin, Maria Alma Rodriguez, Paolo Fiumara, André Goy, Sima Jeha, John T. Manning, Dan Jones, Lynne V. Abruzzo, L. Jeffrey Medeiros
2003130
14
Philadelphia Chromosome–Positive Acute Myeloid Leukemia
American Journal of Clinical Pathology ·Chad P. Soupir, Jo-Anne Vergilio, Paola Dal Cin, Alona Muzikansky, Hagop M. Kantarjian, Dan Jones, Robert P. Hasserjian
2007128
15
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Blood ·Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Jenny Shan, Susan O’Brien, Neeli Reddy, William G. Wierda, Stefan Faderl, Guillermo Garcia‐Manero, Srđan Verstovšek, Mary Beth Rios, Jörge E. Cortes
2008128
16
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
Blood ·Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah A. Thomas, Steven M. Kornblau, Susan O’Brien, Jörge E. Cortes
2009126
17
Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
Blood ·Dushyant Verma, Hagop M. Kantarjian, Dan Jones, Rajyalakshmi Luthra, Gautam Borthakur, Srđan Verstovšek, Mary Beth Rios, Jörge E. Cortes
2009122
18
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories
Blood ·Marco Herling, Joseph D. Khoury, LaBaron T. Washington, Madeleine Duvic, Michael J. Keating, Dan Jones
2004122
19
Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
Blood ·Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Dan Jones, Claude Nicaise, Susan O’Brien, Francis J. Giles, Moshe Talpaz, Jörge E. Cortes
2006121
20
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Blood ·Hagop M. Kantarjian, Charles A. Schiffer, Dan Jones, Jörge E. Cortes
2007118

About Dan Jones

Dan Jones is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Rheumatology, having authored 262 papers that have together received 9.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (90 papers), Chronic Lymphocytic Leukemia Research (85 papers), Lymphoma Diagnosis and Treatment (64 papers), Eosinophilic Disorders and Syndromes (43 papers), Cutaneous lymphoproliferative disorders research (35 papers), Acute Myeloid Leukemia Research (33 papers), Acute Lymphoblastic Leukemia research (22 papers) and Viral-associated cancers and disorders (20 papers). The work is most often cited by research in Hematology (4.7k citations), Genetics (3.6k citations), Rheumatology (1.9k citations), Pathology and Forensic Medicine (2.2k citations) and Dermatology (957 citations). Dan Jones has collaborated with scholars based in United States, Germany and Taiwan. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Guillermo Garcia‐Manero, L. Jeffrey Medeiros, Srđan Verstovšek, Francis J. Giles, Elias Jabbour, Marco Herling and Stefan Faderl. Their work appears in journals such as Blood, American Journal of Clinical Pathology, Cancer, Journal of Clinical Oncology and Modern Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naveen PemmarajuBreakdown of academic impact, for papers by Rajyalakshmi LuthraBreakdown of academic impact, for papers by Steven CoutréBreakdown of academic impact, for papers by James W. VardimanBreakdown of academic impact, for papers by Steven L. AllenBreakdown of academic impact, for papers by Michinori OguraBreakdown of academic impact, for papers by Gert J. OssenkoppeleBreakdown of academic impact, for papers by Tapan M. KadiaBreakdown of academic impact, for papers by Naval DaverBreakdown of academic impact, for papers by Oliver G. Ottmann